Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs

At a Friday meeting FDA co-hosted with ASCO and Friends of Cancer Research, patient advocates expressed concern over their ability to access newly approved tissue-agnostic medicines, as well as clinical trials assessing up-and-coming treatments based on molecular markers rather than tissue of origin. Stakeholders also raised concerns about the lack of access to tumor-profiling technologies and inconsistent approaches

Read the full 582 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE